Comment
Author: Admin | 2025-04-28
Or refractory sarcomas (rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma) treated with etoposide (in combination with ifosfamide and carboplatin) in one of three phase 1/2 trials support the use of etoposide for these refractory sarcomas Van Winkle 2005.Soft tissue sarcomaaData from a prospective, randomized, phase 3 trial support the use of etoposide (in combination with ifosfamide, mesna, and doxorubicin) with regional hyperthermia in patients with localized high-risk soft-tissue sarcoma Issels 2010, Issels 2018.Thymic carcinoma, locally advanced or metastaticcData from a small, prospective study suggest that etoposide (in combination with cisplatin, ifosfamide, and mesna [VIP regimen]) may be of benefit for the treatment of thymic carcinoma Loehrer 2001. Data from a retrospective review also suggest the utility of etoposide (in combination with vincristine, doxorubicin, and cisplatin [CODE regimen]) for managing advanced or unresectable thymic carcinoma Yoh 2003.Thymoma, locally advanced or metastaticbData from 2 prospective studies support the use of etoposide (in combination with cisplatin [PE regimen] or ifosfamide, mesna, and cisplatin [VIP regimen]) for the treatment of advanced, recurrent, or metastatic malignant thymoma Giaccone 1996, Loehrer 2001.Unknown primary adenocarcinomabData from a phase 2 trial in patients with metastatic carcinoma of unknown primary site support the use of oral etoposide (in combination with paclitaxel and carboplatin) for the treatment of this condition Greco 2000. Additional data from a multicenter, phase 2 study in patients with metastatic poorly-differentiated neuroendocrine carcinoma (62% had unknown primary site) who had received no prior treatment demonstrated that etoposide (in combination with paclitaxel and carboplatin) also supports the use of etoposide in this condition Hainsworth 2006. ContraindicationsHypersensitivity to etoposide or any component of the formulationCanadian labeling: Additional contraindications (not in the US labeling): Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment Dosage and AdministrationDosing: AdultAcute lymphoblastic leukemia, relapsed/refractory (off-label use):IV: 100 mg/m2 on days 1 to 5 (in combination with mitoxantrone, ifosfamide, and mesna) as induction therapy; if complete remission occurred following induction, one additional cycle as consolidation therapy was administered (Schiller 1993) or (adults 2 on days 1 to 5 (in combination with clofarabine and cyclophosphamide) as induction (a second 5-day induction cycle may be administered if a partial response occurred), followed by 100 mg/m2 on days 1 to 4 (in combination with clofarabine and cyclophosphamide) as consolidation; a total of up to 4 cycles (induction and consolidation) may be administered (Miano 2012).Acute myeloid leukemia, refractory (off-label use):IV: 80 mg/m2 on days 1 to 6 (in combination with mitoxantrone and cytarabine); if complete remission occurred following induction, an additional cycle of 80 mg/m2 on days 1 to 4 (in combination with mitoxantrone and cytarabine) as consolidation was administered (Amadori 1991) or 100 mg/m2 on days 1 to 5 (in combination with mitoxantrone); if complete remission occurred following
Add Comment